#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

First experiences with treatment of chronic hepatitis C with Pegintron and Rebetol in the Czech Republic


Authors: Jan Šperl Za Kolektiv Autorů
Authors‘ workplace: Institut klinické a experimentální medicíny v Praze Klinika hepatogastroenterologie Přednosta Doc. MUDr. Julius Špičák, CSc.
Published in: Vnitř Lék 2005; 51(11): 1314-1318
Category: Non-reviewed articles

Overview

Based on retrospectively collected data, the team evaluated results for treatment of the first hundred of patients treated for chronic hepatitis C with PegIntron and Rebetol in the Czech Republic between 2003 and 2005. The treatment resulted in sustained virological response (SVR) in 53 out of 100 patients (53.0%). The effect of treatment was highest for patients without previous treatment, with SVR ratio 34 versus 53 (62.2%). The effect of treatment was lower in patients who relapsed after previous treatment with conventional interferon-α or showed no response to treatment at all, with SVR ratio 14 versus 27 (51.9%), and 5 versus 20 (25.0%), respectively. The effect of treatment in patients with genotype 1 was comparable with that in patients for whom genotype was not available, with SVR ratio 35 versus 65 (58%), and 14 versus 25 (56%), respectively, but we assume genotype 1 prevalence in the latter group, too. The effect of PegIntron and Rebetol in treatment of chronic hepatitis C in Czech patients coincides with results reported in published clinical studies.

Keywords:
chronic hepatitis C – PegIntron – Rebetol – virological response


Sources

1.Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa–2b plus ribavirin compared with interferon alfa–2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 22 (358): 958–965.

2.Davis GL, Wong JB, McHutchison JG et al. Early virological response to treatment with peginterferon alfa–2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–652.

3.Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa–2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–1023.

4.Urbánek P, Husa P, Šperl J et al.: Diagnostika a léčba chronické hepatitidy C. Doporučený postup české hepatologické společnosti a společnosti infekčního lékařství čLS JEP. Klinická mikrobiologie a infekční lékařství 2005; 11: 149–196.

5.McHutchison JG, Manns M, Patel K et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype–1–infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.

6.Lindsay KL, Trepo C, Heintges T, Shiffman ML et al. Hepatitis Interventional Therapy Group. A randomized, double–blind trial comparing pegylated interferon alfa–2b to interferon alfa–2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403.

7.Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa–2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–9. Erratum in: J Hepatol. 2005, 42: 434.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 11

2005 Issue 11

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#